Injection for New Drug Candidate Programmes

A €3.5M ($3.9M) investment from existing shareholder Seventure Partners, to accelerate the development of its programmes targeting membrane receptors in Central Nervous System (CNS) disorders; oncology/immuno-oncology and rare diseases, has been announced by Domain Therapeutics

The company successfully executed on the three pillars of its business strategy in 2018, thanks to a multitarget collaboration agreement with Boehringer Ingelheim, a license granted on the bioSens-All™ technology platform to BMS and the acquisition by Lundbeck of Prexton Therapeutics, one of the asset-centric companies developing Strasbourg-based Domain’s programs.

“Seventure Partners is proud to be a strategic financial partner for Domain Therapeutics, a company with validated breakthrough technologies,” said Sébastien Groyer, Partner, Seventure Partners. “Since our last investment in the company, Pascal Neuville and his team have significantly expanded the business and increased the value of the company.”

“With Domain being a profitable biotech, the support of Seventure aims at kick-starting our acceleration phase,” said Pascal Neuville, CEO of Domain Therapeutics. “This recognition by a major shareholder of our capacity to create value is a positive signal for future investors and will pave the way for a significant investment aimed at further speeding up company growth.”